1544P A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations
M. Kansara(UNSW Sydney), D. Thomas(UNSW Sydney), Theresa M. Corpuz(UNSW Sydney), P.S. Kok(The University of Sydney), Rosemary Harrup(University of Tasmania), Michael Millward(The University of Western Australia), K.J. O'Byrne(Princess Alexandra Hospital), H. Thomas(The University of Sydney), M. Ballinger, Subotheni Thavaneswaran(The University of Sydney), J. Desai(Peter MacCallum Cancer Centre), S. Selva‐Nayagam(Royal Adelaide Hospital), John Simes(The University of Sydney), P. Grimison(Chris O’Brien Lifehouse), James J. Grady(UNSW Sydney), Michail Charakidis(Royal Adelaide Hospital), Jie Lu(Zhengzhou University), Paul Craft(Canberra Hospital), F.P. Lin(The University of Sydney), Piyushkumar A. Mundra(Children's Cancer Institute Australia)
Cited by 1
Related Papers
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
|The Lancet|2022|255
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
|The Lancet Diabetes & Endocrinology|2024|148
Association of weight-adjusted-waist index with incident hypertension: The Rural Chinese Cohort Study
|Nutrition Metabolism and Cardiovascular Diseases|2020|125